Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Mar;65(3):351–354. doi: 10.1038/bjc.1992.71

Enhancement of dopaminergic agonist bromocriptine of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats.

H Iishi 1, M Baba 1, M Tatsuta 1, S Okuda 1, H Taniguchi 1
PMCID: PMC1977621  PMID: 1558787

Abstract

The effects of the dopamine agonist 2-bromo-alpha-ergocryptine methanesulfonate (bromocriptine) on the incidence, number and histology of gastric cancer induced by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) were investigated in Wistar rats. Rats were given 1 or 2 mg kg-1 body weight of bromocriptine subcutaneously every other day in depot form after 25 weeks of oral treatment with MNNG. Prolonged administration of bromocriptine at both dosages every other day resulted in a significant increase in the incidence and number of gastric cancers of the glandular stomach by week 52. Bromocriptine treatment did not influence the histological type of gastric cancer, but caused a significant increase in the labelling index of epithelial cells of the antrum. These findings indicate that the dopamine agonist bromocriptine promotes gastric carcinogenesis, and that this effect may be related to its effect in increasing proliferation of epithelial cells in the antral mucosa.

Full text

PDF
351

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANTON A. H., SAYRE D. F. A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines. J Pharmacol Exp Ther. 1962 Dec;138:360–375. [PubMed] [Google Scholar]
  2. Baksi S. N., Hughes M. J., Strahlendorf H. K. Adrenal catecholamine concentration after chronic treatment with bromocriptine and haloperidol. J Pharm Pharmacol. 1986 Oct;38(10):774–776. doi: 10.1111/j.2042-7158.1986.tb04491.x. [DOI] [PubMed] [Google Scholar]
  3. Brodde O. E. Vascular dopamine receptors: Demonstration and characterization by in vitro studies. Life Sci. 1982 Jul 26;31(4):289–306. doi: 10.1016/0024-3205(82)90406-4. [DOI] [PubMed] [Google Scholar]
  4. Gerson S. C., Baldessarini R. J. Motor effects of serotonin in the central nervous system. Life Sci. 1980 Oct 20;27(16):1435–1451. doi: 10.1016/0024-3205(80)90368-9. [DOI] [PubMed] [Google Scholar]
  5. Gratzner H. G. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science. 1982 Oct 29;218(4571):474–475. doi: 10.1126/science.7123245. [DOI] [PubMed] [Google Scholar]
  6. Guldvog I., Linnestad P., Schrumpf E., Berstad A. Dopaminergic and adrenergic influence on gastric acid and pepsin secretion stimulated by food. The role of vagal innervation. Scand J Gastroenterol Suppl. 1984;89:113–116. [PubMed] [Google Scholar]
  7. Hernandez D. E., Mason G. A., Walker C. H., Valenzuela J. E. Dopamine receptors in human gastrointestinal mucosa. Life Sci. 1987 Dec 21;41(25):2717–2723. doi: 10.1016/0024-3205(87)90464-4. [DOI] [PubMed] [Google Scholar]
  8. Kusunoki M., Taniyama K., Tanaka C. Dopamine regulation of [3H]acetylcholine release from guinea-pig stomach. J Pharmacol Exp Ther. 1985 Sep;234(3):713–719. [PubMed] [Google Scholar]
  9. Morstyn G., Hsu S. M., Kinsella T., Gratzner H., Russo A., Mitchell J. B. Bromodeoxyuridine in tumors and chromosomes detected with a monoclonal antibody. J Clin Invest. 1983 Nov;72(5):1844–1850. doi: 10.1172/JCI111145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Nishikawa H., Yokotani K., Fujiwara M. Catecholamine receptors involved in the inhibitory effects of dopamine on vagally stimulated gastric acid secretion and mucosal blood flow in rats. J Pharmacol Exp Ther. 1987 Mar;240(3):966–971. [PubMed] [Google Scholar]
  11. Rattan S., Goyal R. K. Effect of dopamine on the esophageal smooth muscle in vivo. Gastroenterology. 1976 Mar;70(3):377–381. [PubMed] [Google Scholar]
  12. Scemama J. L., Ruellan C., Clerc P., Clemente F., Ribet A. Dopamine receptors in a human colonic cancer cell line (HT29). Some receptor-related biological effects of dopamine. Int J Cancer. 1984 Nov 15;34(5):675–679. doi: 10.1002/ijc.2910340515. [DOI] [PubMed] [Google Scholar]
  13. Steardo L., Di Stasio E., Bonuso S., Maj M. The effect of bromocriptine on plasma catecholamine concentrations in normal volunteers. Eur J Clin Pharmacol. 1986;29(6):713–715. doi: 10.1007/BF00615964. [DOI] [PubMed] [Google Scholar]
  14. Stefanini M., De Martino C., Zamboni L. Fixation of ejaculated spermatozoa for electron microscopy. Nature. 1967 Oct 14;216(5111):173–174. doi: 10.1038/216173a0. [DOI] [PubMed] [Google Scholar]
  15. Tatsuta M., Baba M., Itoh T. Increased gastrin secretion in patients with pheochromocytoma. Gastroenterology. 1983 May;84(5 Pt 1):920–923. [PubMed] [Google Scholar]
  16. Tatsuta M., Iishi H., Baba M. Inhibition by neostigmine and isoproterenol and promotion by atropine of experimental carcinogenesis in rat stomach by N-methyl-N'-nitro-N-nitrosoguanidine. Int J Cancer. 1989 Jul 15;44(1):188–189. doi: 10.1002/ijc.2910440134. [DOI] [PubMed] [Google Scholar]
  17. Tatsuta M., Iishi H., Yamamura H., Baba M., Yamamoto R., Taniguchi H. Effect of cimetidine on inhibition by tetragastrin of carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Cancer Res. 1988 Mar 15;48(6):1591–1595. [PubMed] [Google Scholar]
  18. Valenzuela J. E. Dopamine as a possible neurotransmitter in gastric relaxation. Gastroenterology. 1976 Dec;71(6):1019–1022. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES